B-cell acute lymphoblastic leukemia pediatric · 7 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Imatinib-based consolidation Variant #01 | BCR::ABL1 | R 12 464 | 28d | — | — | ~1 | ~R 12 464 indirect | — |
Etoposide and TBI, then allo HSCT Variant #03 Partial | — | R 6 770 | — | — | — | ~1 | ~R 6 770 indirect | — |
Etoposide, Ifosfamide, Imatinib Variant #01 | BCR::ABL1 | R 6 394 | 21d | — | — | ~1 | ~R 6 394 indirect | — |
Augmented BFM consolidation Variant #01 Partial | — | R 6 249 | 63d | — | — | ~1 | ~R 6 249 indirect | — |
AALL0232 consolidation Variant #01 Partial | — | R 6 249 | 50d | — | — | ~1 | ~R 6 249 indirect | — |
Mercaptopurine and Vincristine Variant #01 | — | R 4 095 | 28d | — | — | ~1 | ~R 4 095 indirect | — |
Cyclophosphamide and TBI, then allo HSCT Variant #01 Partial | — | R 1 176 | — | — | — | ~1 | ~R 1 176 indirect | — |
7 of 7 regimens shown